

ASX Release

Anatara Investor Update

Highlights:

- **Anatara on track for the 2017 launch of its lead product, Detach™**
- **Focus remains on livestock applications for Detach™, while strategically moving focus to human “gut” related disorders**
- **Human market is lucrative with unmet medical need**

BRISBANE, 22nd November 2016: Anatara Lifesciences (ASX: ANR) is pleased to release its updated investor presentation.

The Company remains well positioned for the launch of Detach™, its non-antibiotic treatment for gastrointestinal disease. Initially focused on pigs, launch is expected in 2017 and follows the Anatara’s application in October to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for approval to sell and market Detach™.

Chairman and CEO, Dr Mel Bridges commented, “With our APVMA submission complete, while the team will continue to focus on livestock applications, our focus will increasingly turn to applications for human health – particularly gut health and gastrointestinal disorders. There is significant opportunity for Anatara in this area,” Dr Bridges added.

With around four billion episodes of diarrhoea in the world annually, this represents a serious area of unmet medical need and one which Anatara can potentially address using its core technology. Diarrhoea is the second cause of death in children under 5 years of age and the leading cause of malnutrition.

Anatara’s Chief Scientific Officer, Dr Tracey Mynott said, “The anti-secretory and anti-inflammatory action of Detach™ actives open the way to treat human gastrointestinal conditions such as Irritable Bowel Syndrome, Inflammatory Bowel Disease and Traveller’s Diarrhoea. These are significant areas of unmet medical need that are not addressed by current products,” Dr Mynott added.

Anatara will keep the market updated as it moves through the APVMA approval process and development of the Company’s human program.



For more information please contact:

Investor inquiries	Media inquiries
Dr Mel Bridges Chairman & CEO, Anataro Lifesciences +61 (0) 413 051 600 mbridges@anataralifesciences.com Dr Tracey Mynott CSO, Anataro Lifesciences +61 (0) 405 050 113 tmynott@anataralifesciences.com	Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anataro Lifesciences

Anataro Lifesciences (ASX: ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anataro team has a strong track record in biological science as well as building and growing international biotech companies. Please see www.anataralifesciences.com for further background.



ANATARA
LIFESCIENCES

Investor Update

November 2016



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Key Financial Details

ASX Code ANR	Market Capitalisation \$54.4 million	Share Price¹ \$1.10
Current Cash² \$13.8 million	Ordinary Shares 49,413,236	Share Price up 162% since IPO

1. As at 14 November 2016
2. Appendix 4E - 30 June 2016



ANR Share Price Chart



Oral therapeutics for gastrointestinal disease in livestock and humans

Detach™

- Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea
- Meets the need to reduce the use of antibiotics in animal production
- Unlike antibiotics, Detach™ will not contribute to antimicrobial resistance



Need to combat antimicrobial resistance

resistance to antibiotics ‘....*the greatest and most urgent global risk*’

General Assembly of the United Nations 2016


Antibiotic resistance driven by the overuse of antibiotics

- **10 million**: the number of people who will die every year due to AMR by 2050
- **\$100 trillion**, the estimated total GDP that will be lost globally by 2050 if AMR isn't tackled



Lead Indication – Pigs

Diarrhoea affects hundreds of millions of piglets born each year



Millions of piglets weaned per year

20% more piglets die before weaning due to health issues



Market Opportunity is clear

- Detach™ addresses a **major need** – the livestock industry need effective alternatives to antibiotics to prevent diarrhoea
- Governments are banning antibiotics for growth promotion and restricting prophylactic use in animal production
- Global animal antibiotic market valued at ~ \$4.6 billion in 2014¹. Production animals 70%. Pigs lead by market share of 25%.
- Pork is #1 consumed meat in the world
- Global demand for meat is rising. More than 85% more meat needed by 2030².
- Consumers want their meat to be safe
- Retailers are pledging to offer '*antibiotic free*' meat



FY16 – Key Achievements

Milestone

Partnering


Zoetis have exclusive worldwide right (excl. AU/NZ) to evaluate Detach™ for veterinary use in livestock

Animal safety trials

Detach™ proven safe in piglets even when administered at 5x and more frequent than the recommended dose

Submission of dossier to APVMA

Anatara's application for registration of Detach was lodged with the APVMA (post reporting period).



Detach™

Poised for swift market entry

Commercially validated, supported by demand

- A clear path to market: Launch in 2017
 - Proven efficacy on commercial pig farms (therapeutic claims)
 - Proven safety (active ingredient is GRAS)
 - Manufacturing complete at commercial scale and global supply confirmed
- Introduction of Detach™ is supported by industry, government, retailer & consumer demand
- Detach™ will be supplied in Australia via pre-existing distribution channels (Australian pork industry is heavily consolidated)
- Focus now is on planning market Launch



Current 50 kg scale
(≈500,000 doses)



1,000 kg capacity
(≈8,500,000 doses)





ANATARA
LIFESCIENCES

Human Applications

There are 4 billion episodes of diarrhoea in the world annually.

Diarrhoea is the second cause of death in children under 5 years, and the leading cause of malnutrition.



Anatara technology – for humans

Anti-secretory and anti-inflammatory action of Detach™ actives to treat human gastrointestinal conditions, such as:

- Irritable bowel syndrome
- Inflammatory bowel disease and
- Traveller's diarrhoea


Significant unmet need not addressed by current products

Wide consumer knowledge

- Google “gut health books”



Google 'GUT Health Books'



Human GI disorders/disease

-Large patient populations



Traveller's diarrhoea

50 million
travellers at risk per year.
Rising to 100 million by 2020.



TD is a threat to military efficiency
and preventative treatment is a
priority for the US Army



Developing countries

#2 cause of death in under 5's
(1.3 million kids per year.)



United States of America




~ 211-375m episodes of diarrhoea p.a.
116m people use anti-diarrhoea medication (31%).



Irritable Bowel Syndrome

- *The most commonly diagnosed gastrointestinal condition and a significant health care burden*
- Is a functional disorder. Incomplete knowledge of pathology, therefore treatment is symptom management
- Problem is diverse, including abdominal pain, bloating and alternating constipation and diarrhoea
- Patients have a poor quality of life and utilise the healthcare system more than other patients
- Prevalence varies globally. Affects 20% of USA population



IBS Current Therapies


Estimated average annual cost of therapy is \$3,882

- Symptom-based treatments, as no detectable cause
 - Anti-spasmodics for pain - Buscopan (Boehringer Sohn, CH) is the brand leader globally - 39% of the market
 - Fibre, bulking agents and anti-diarrhoeals (eg. Loperamide & diphenoxylate HCl-atropine), for diarrhoea
 - Charcoal resins, antifatulents, and other agents for bloating, distension, and flatulence
 - Lotronex (alosetron hydrochloride), 5-HT₃ (serotonin) antagonist
 - Probiotics
 - Anti-depressants
- 50% of IBS patients turn to herbal preparations



Inflammatory Bowel Disease

- Two forms, Ulcerative Colitis and Crohn's disease
- Patients experience abdominal pain and cramping, bloating, blood and mucus in the stool, loss of appetite and persistent diarrhoea
- No cure
- Treatment involves suppressing inflammation with the goal of inducing and maintaining remission.
- A recent study¹ has also implicated overuse of antibiotics in the development in paediatric IBD.



IBD Current Therapies¹

Average annual cost per patient is \$5,066 to \$18,963

5-ASA (5-aminosalicylic acid) > \$2 billion/year (USA)

eg. Azulfidine (Pfizer)

Average annual cost of therapy is \$321/patient (less than \$1 per tablet²)

Side effects and resistance is common

Corticosteroids > US\$3.6 billion/year² eg. Prednisone

Average annual cost of therapy is \$855/patient

Effective for acute attacks

Not suitable for long term use because of side effects

Biologicals (anti-TNF mAb's) > \$25 billion²


eg. Remicade (Janssen, USA – Merck) (\$7.8 billion), Humira (Abbvie) (\$7.9 billion)

Average annual cost of therapy is \$21,000. Tysabri (USA \$54,808 per patient per year)

Expensive. Governments (EU) don't want to pay for expensive biologics

Require injection

All have significant side effects. FDA Black Box warnings



Anatara - Human GI Product Opportunity

IBS and IBD are distinct diseases, but have common symptoms

Increasing overlap in the treatment of IBD and IBS¹.


A significant opportunity exists for compounds that can be administered orally, with a similar or better therapeutic effect, ***and low side effect profile*** to existing IBS and IBD treatments

Anatara have the potential to provide such treatments – have a significant safety profile



Detach™ - leverage Pigs to People

Anatara's commercialisation strategy



Detach™
- From Pigs
to People

- Same mechanism of action for treatment of disease in pigs and humans
- Pre-clinical program for animals complete therefore development for humans de-risked
- Clinic ready (CMC, Toxicology, Pharmacology well developed)
- Ready to Partner/Develop



ANATARA LIFESCIENCES

Detach™ for Humans – well advanced


Status

- Mode of action clearly understood, based on decades of research
- Pre-clinical efficacy database is very strong due to leverage of Detach™ data from pig studies
- Proof of concept in several animal models
- Confirmed efficacy in rabbit models with human diarrhoea pathogens
- Proof of concept in mouse model of inflammatory bowel disease
- Margin of safety studies (1x, 3x and 5x dose) in piglets completed (TAS study)
- Human Safety studies (Phase I) in healthy volunteers completed
 - 28 day treatment was very well tolerated



Market Opportunity: Human GI disorders/disease


- Substantial patient population with unmet need despite availability of numerous therapies
- GI disorders are highly symptomatic and the most common reason why people seek medical treatment^{1,2}
- GI disorders are associated with significant quality-of-life issues because of pain and abnormal bowel habits
- Huge need for effective therapies that are safe enough for chronic use
- Huge need for products that prevent disease or relapse
- Major Pharma have significant interest in GI therapeutic area



Development Options

Anatara compounds are from a natural source, so there are several development options.

1. Pharmaceutical Development (Single molecular entity)
2. Over the Counter (OTC) - Natural Health Products, Complementary Medicine, Medical Foods, Botanical Drugs (Proprietary Extracts)



Strategic decision to move forward with OTC products first – offers fastest route to market.



Consumers Want Natural Products

- Concern about adverse effects of conventional drugs with suboptimal efficacy
- 50% of IBS patients and 21% of IBD patients use OTC products to do everything possible to control their disease
- Patients perceive natural products offer a gentler way of managing chronic conditions
- People increasingly worried about their health take prevention of illness into their own hands
- Major Pharma have consumer health businesses or a focus on “wellness” - Large focus on plant botanicals
- Natural products work - By 1990, approximately 80% of drugs were either natural products (or analogs inspired by them).
 - Eg. Antibiotics (e.g., penicillin, tetracycline, erythromycin)
 - Anti-malarials (e.g., quinine, artemisinin)
 - Lipid control agents (e.g., lovastatin and analogs)
 - Anti-cancer drugs (e.g., taxol, doxorubicin)



Thank you

Anatara's naturally derived compounds offer a safe but effective alternative to antibiotics for gastrointestinal diseases and the Company is uniquely positioned to fulfil a currently unmet need in the huge, global animal health market.

Dr Mel Bridges, CEO & Chairman, Anatara Lifesciences

Dr Mel Bridges, CEO, Chairman & Co-founder
mbridges@anataralifesciences.com
+61 413 051 600


Dr Tracey Mynott, CSO & Co-founder
tmynott@anataralifesciences.com
+61 405 050 113



Detach™ Mode of action

Detach™ does not target the pathogen

Detach™ acts on the underlying cause of diarrhoea



1. Chandler and Mynott. 1998. *Gut* 43:196-202
2. Mynott, et al., 1996. *Gut* 38:28-32
3. Mynott, et al. 1997. *Gastroenterol.* 113:175-184
4. Mynott et al. 1999. *J. Immunol.* 163:2568-2575



Intellectual Property

- PCT application filed (August 2015)
- Second PCT application filed (August 2016)
- Solid patent strategy in place for further patents to be filed in major territories
- Claims cover the Detach™ formulation, as well as use of the active ingredient and composition of matter for the active components within Bromelain-Rx
- Bromelain-Rx is not the same as common bromelain
- Detach™ formulation has superior efficacy to bromelain or bromelain-Rx alone



IP wall of China

